# Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction

Study · id `cardio:ct-nct05387967` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05387967](<https://clinicaltrials.gov/study/NCT05387967>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05387967

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.

## Technical summary

Registry record NCT05387967. Allocation not applicable; no masking; primary purpose treatment. Start 2021-01-01 (actual); primary completion 2021-06-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 121 participants (enrolled count; ClinicalTrials.gov record NCT05387967, source copy `cardio:ctgov-nct05387967-2022-05-24`, retrieved 2026-10-26)
- Started: 2021-01-01 (actual) (ClinicalTrials.gov record NCT05387967, source copy `cardio:ctgov-nct05387967-2022-05-24`, retrieved 2026-10-26)
- Primary completion: 2021-06-30 (actual) (ClinicalTrials.gov record NCT05387967, source copy `cardio:ctgov-nct05387967-2022-05-24`, retrieved 2026-10-26)
- Completion: 2021-09-30 (actual) (ClinicalTrials.gov record NCT05387967, source copy `cardio:ctgov-nct05387967-2022-05-24`, retrieved 2026-10-26)
- Countries: Pakistan (ClinicalTrials.gov record NCT05387967, source copy `cardio:ctgov-nct05387967-2022-05-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05387967-2022-05-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction
- Condition: Heart Failure, Systolic
- Intervention (Drug): Sacubitril/valsartan
- Lead sponsor: National Institute of Cardiovascular Diseases, Pakistan
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Sacubitril/valsartan (combination) (`cardio:sacubitril-valsartan`)
- Registry lists this organization as the lead sponsor: National Institute of Cardiovascular Diseases, Pakistan (`cardio:org-national-institute-of-cardiovascular-diseases-pakistan`)

## Provenance

Content hash: 989f9a0665f5a3924d14a13d21b55978dba5f86ff4264b8a19bd8882bc57a0da
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
